JP2010510801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510801A5 JP2010510801A5 JP2009538805A JP2009538805A JP2010510801A5 JP 2010510801 A5 JP2010510801 A5 JP 2010510801A5 JP 2009538805 A JP2009538805 A JP 2009538805A JP 2009538805 A JP2009538805 A JP 2009538805A JP 2010510801 A5 JP2010510801 A5 JP 2010510801A5
- Authority
- JP
- Japan
- Prior art keywords
- fgf receptor
- fusion
- cancer
- modified soluble
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091008794 FGF receptors Proteins 0.000 claims 47
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims 47
- 230000004927 fusion Effects 0.000 claims 38
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 4
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 4
- 230000004988 N-glycosylation Effects 0.000 claims 4
- 102000002262 Thromboplastin Human genes 0.000 claims 4
- 108010000499 Thromboplastin Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 2
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 101800004937 Protein C Proteins 0.000 claims 2
- 102000017975 Protein C Human genes 0.000 claims 2
- 229940096437 Protein S Drugs 0.000 claims 2
- 102000029301 Protein S Human genes 0.000 claims 2
- 108010066124 Protein S Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 101800001700 Saposin-D Proteins 0.000 claims 2
- 201000010208 Seminoma Diseases 0.000 claims 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 2
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940044684 anti-microtubule agent Drugs 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 230000022131 cell cycle Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000003668 hormone analog Substances 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- -1 platinum coordination complex Chemical class 0.000 claims 2
- 230000000861 pro-apoptotic effect Effects 0.000 claims 2
- 229960000856 protein c Drugs 0.000 claims 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 2
- 125000005629 sialic acid group Chemical group 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229940063683 taxotere Drugs 0.000 claims 2
- 208000001608 teratocarcinoma Diseases 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 102100035838 Lactosylceramide 4-alpha-galactosyltransferase Human genes 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical group [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 108010070808 UDP-galactose-lactosylceramide alpha 1-4-galactosyltransferase Proteins 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000003699 striated muscle Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06291824 | 2006-11-28 | ||
| EP07290042 | 2007-01-11 | ||
| PCT/IB2007/004354 WO2008065543A2 (en) | 2006-11-28 | 2007-11-28 | Modified soluble fgf receptor fc fusions with improved biological activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510801A JP2010510801A (ja) | 2010-04-08 |
| JP2010510801A5 true JP2010510801A5 (https=) | 2010-09-09 |
Family
ID=39431092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538805A Pending JP2010510801A (ja) | 2006-11-28 | 2007-11-28 | 生物学的活性が向上した修飾可溶性ＦＧＦ受容体Ｆｃ融合物 |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US8119770B2 (https=) |
| EP (1) | EP2092069B2 (https=) |
| JP (1) | JP2010510801A (https=) |
| KR (1) | KR20090102769A (https=) |
| AR (1) | AR063975A1 (https=) |
| AT (1) | ATE509106T1 (https=) |
| AU (1) | AU2007326985C1 (https=) |
| BR (1) | BRPI0719290A2 (https=) |
| CA (1) | CA2668932A1 (https=) |
| CL (1) | CL2007003411A1 (https=) |
| CO (1) | CO6190564A2 (https=) |
| CR (1) | CR10777A (https=) |
| CY (1) | CY1112435T1 (https=) |
| DK (1) | DK2092069T3 (https=) |
| EA (1) | EA018700B1 (https=) |
| EC (1) | ECSP099361A (https=) |
| GT (1) | GT200900137A (https=) |
| HR (1) | HRP20110503T1 (https=) |
| IL (1) | IL198480A0 (https=) |
| MA (1) | MA31143B1 (https=) |
| MX (1) | MX2009005692A (https=) |
| MY (1) | MY145914A (https=) |
| NI (1) | NI200900097A (https=) |
| NO (1) | NO20092414L (https=) |
| PE (1) | PE20081250A1 (https=) |
| PL (1) | PL2092069T3 (https=) |
| PT (1) | PT2092069E (https=) |
| RS (1) | RS51911B (https=) |
| SI (1) | SI2092069T1 (https=) |
| SV (1) | SV2009003272A (https=) |
| TN (1) | TN2009000184A1 (https=) |
| TW (1) | TW200839012A (https=) |
| WO (1) | WO2008065543A2 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7850970B2 (en) | 2003-08-26 | 2010-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| EP2318529B1 (en) | 2008-08-04 | 2017-10-18 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| US8445445B2 (en) | 2009-09-15 | 2013-05-21 | Five Prime Therapeutics, Inc. | Method of promoting hair growth using FGFR4 extracellular domains |
| LT2498799T (lt) * | 2009-11-13 | 2016-11-10 | Five Prime Therapeutics, Inc. | Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis |
| WO2011084711A2 (en) | 2009-12-17 | 2011-07-14 | Five Prime Therapeutics, Inc. | Hair growth methods using fgfr3 extracellular domains |
| FR2958936A1 (fr) | 2010-04-14 | 2011-10-21 | Sanofi Aventis | Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs |
| KR101910779B1 (ko) * | 2010-11-15 | 2018-10-22 | 파이브 프라임 테라퓨틱스, 인크. | Ｆｇｆｒ１ 세포밖 도메인 조합치료 |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| AU2015258172B2 (en) * | 2010-11-15 | 2017-01-12 | Five Prime Therapeutics, Inc. | Fgfr1 extracellular domain combination therapies |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| JP2014507395A (ja) | 2010-12-23 | 2014-03-27 | サノフイ | 肝癌の治療における使用のためのＲｏｂｏ１−Ｆｃ融合タンパク質 |
| AR085302A1 (es) * | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| CN102219859B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | 拮抗血管新生诱导因子的融合蛋白及其用途 |
| CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| WO2012178102A2 (en) | 2011-06-24 | 2012-12-27 | The Regents Of The Unversity Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| CN107823630A (zh) * | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
| CA2896951A1 (en) | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| EA201591324A1 (ru) | 2013-01-16 | 2016-01-29 | Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета |
| MX2015011428A (es) | 2013-03-06 | 2016-02-03 | Genentech Inc | Metodos para tratar y prevenir la resistencia a los farmacos para el cancer. |
| US9701753B2 (en) | 2013-03-11 | 2017-07-11 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
| US9957313B2 (en) | 2013-03-15 | 2018-05-01 | Remegen, Ltd. | FGFR-FC fusion proteins and the use thereof |
| KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| SG10201703977UA (en) * | 2013-05-23 | 2017-06-29 | Five Prime Therapeutics Inc | Methods of treating cancer |
| KR102516152B1 (ko) | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| WO2015143091A1 (en) | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
| MX2018006181A (es) * | 2015-11-23 | 2018-09-24 | Five Prime Therapeutics Inc | Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer. |
| PT3624837T (pt) | 2017-05-16 | 2025-10-01 | Five Prime Therapeutics Inc | Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro |
| KR20190065234A (ko) * | 2017-11-30 | 2019-06-11 | 그리폴스 다이어그노스틱 솔루션즈 인크. | 면역 관문 억제제인 pd-1 및 pd-l1에 대한 항체 치료를 모니터링하기 위한 면역분석 및 조작된 단백질 |
| US12448415B2 (en) * | 2018-01-04 | 2025-10-21 | Washington University | Compositions and methods for inhibition of alphavirus infection |
| CR20200327A (es) * | 2018-01-26 | 2020-11-05 | Genentech Inc | Proteínas de fusión fc il-22 y métodos de uso |
| CN120192414A (zh) | 2019-04-03 | 2025-06-24 | 建新公司 | 具有降低的断裂的抗αβTCR结合多肽 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288856A (en) | 1986-11-20 | 1994-02-22 | Pierre Amiguet | Method of isolating acid-stable, biologically active proteins |
| JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5750375A (en) * | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
| US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
| US5288855A (en) * | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5153310A (en) * | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
| HU215581B (hu) * | 1989-07-06 | 1999-01-28 | Regents Of The University Of California | Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására |
| WO1991017183A1 (en) * | 1990-04-27 | 1991-11-14 | Takeda Chemical Industries, Ltd. | Proteins with fibroblast growth factor receptor activity |
| US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| EP0538404B1 (en) | 1990-07-06 | 2003-06-18 | Rhone-Poulenc Rorer International (Holdings) Inc. | Fibroblast growth factor receptors |
| US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US20020045207A1 (en) * | 1997-10-31 | 2002-04-18 | Lynne A. Krummen | Glycoprotein production process |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6656728B1 (en) * | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| US6612152B2 (en) * | 1999-05-01 | 2003-09-02 | James E. Keaton | Lifting, servicing, and diagnosing automobiles |
| US6656738B1 (en) * | 1999-11-17 | 2003-12-02 | Bae Systems Integrated Defense Solutions Inc. | Internal heater for preconcentrator |
| CA2412882A1 (en) * | 2000-06-30 | 2002-01-10 | Maxygen Aps | Peptide extended glycosylated polypeptides |
| CA2953239A1 (en) * | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| EP1553975B8 (en) * | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| AU2004265226A1 (en) | 2003-05-16 | 2005-02-24 | Receptor Biologix, Inc. | Intron fusion proteins, and methods of identifying and using same |
| AU2004280066A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Genomically modified cell |
| DE102004022895A1 (de) | 2004-05-10 | 2005-12-08 | Adam Opel Ag | Schallabsorbierendes Verkleidungselement |
| EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| US20060223147A1 (en) | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| US20060234347A1 (en) | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| EP1746161A1 (en) * | 2005-07-20 | 2007-01-24 | Cytheris | Glycosylated IL-7, preparation and uses |
| EP2083081A1 (en) * | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
-
2007
- 2007-11-27 AR ARP070105241A patent/AR063975A1/es not_active Application Discontinuation
- 2007-11-27 CL CL200703411A patent/CL2007003411A1/es unknown
- 2007-11-27 PE PE2007001663A patent/PE20081250A1/es not_active Application Discontinuation
- 2007-11-28 SI SI200730682T patent/SI2092069T1/sl unknown
- 2007-11-28 AU AU2007326985A patent/AU2007326985C1/en not_active Ceased
- 2007-11-28 EP EP07866627.8A patent/EP2092069B2/en active Active
- 2007-11-28 JP JP2009538805A patent/JP2010510801A/ja active Pending
- 2007-11-28 PL PL07866627T patent/PL2092069T3/pl unknown
- 2007-11-28 TW TW096145220A patent/TW200839012A/zh unknown
- 2007-11-28 BR BRPI0719290-8A patent/BRPI0719290A2/pt not_active IP Right Cessation
- 2007-11-28 WO PCT/IB2007/004354 patent/WO2008065543A2/en not_active Ceased
- 2007-11-28 DK DK07866627.8T patent/DK2092069T3/da active
- 2007-11-28 RS RS20110324A patent/RS51911B/sr unknown
- 2007-11-28 CA CA002668932A patent/CA2668932A1/en not_active Abandoned
- 2007-11-28 HR HR20110503T patent/HRP20110503T1/hr unknown
- 2007-11-28 PT PT07866627T patent/PT2092069E/pt unknown
- 2007-11-28 KR KR1020097013421A patent/KR20090102769A/ko not_active Ceased
- 2007-11-28 EA EA200970515A patent/EA018700B1/ru not_active IP Right Cessation
- 2007-11-28 MY MYPI20092137A patent/MY145914A/en unknown
- 2007-11-28 AT AT07866627T patent/ATE509106T1/de active
- 2007-11-28 MX MX2009005692A patent/MX2009005692A/es active IP Right Grant
- 2007-11-28 US US12/515,463 patent/US8119770B2/en not_active Expired - Fee Related
-
2009
- 2009-04-30 IL IL198480A patent/IL198480A0/en unknown
- 2009-05-07 CR CR10777A patent/CR10777A/es not_active Application Discontinuation
- 2009-05-08 TN TNP2009000184A patent/TN2009000184A1/fr unknown
- 2009-05-20 GT GT200900137A patent/GT200900137A/es unknown
- 2009-05-25 EC EC2009009361A patent/ECSP099361A/es unknown
- 2009-05-26 SV SV2009003272A patent/SV2009003272A/es unknown
- 2009-05-26 CO CO09053830A patent/CO6190564A2/es not_active Application Discontinuation
- 2009-05-27 NI NI200900097A patent/NI200900097A/es unknown
- 2009-06-24 NO NO20092414A patent/NO20092414L/no not_active Application Discontinuation
- 2009-06-24 MA MA32042A patent/MA31143B1/fr unknown
-
2011
- 2011-08-09 CY CY20111100764T patent/CY1112435T1/el unknown
-
2012
- 2012-01-11 US US13/348,297 patent/US8481487B2/en not_active Expired - Fee Related
-
2013
- 2013-06-28 US US13/931,184 patent/US20140030265A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510801A5 (https=) | ||
| HRP20110503T1 (hr) | MODIFICIRANE FUZIJE IZMEĐU TOPIVOG FGF RECEPTORA I Fc, S POBOLJŠANOM BIOLOŠKOM AKTIVNOŠĆU | |
| KR100659477B1 (ko) | 개선된 약물동태학적 성질을 가지는 변형된 키메라 폴리펩티드 | |
| ES2800330T3 (es) | Composiciones que comprenden Anticuerpos anti-IGF-1R y Métodos para obtener dichos Anticuerpos | |
| CA3091140A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer | |
| Zwick et al. | Receptor tyrosine kinase signalling as a target for cancer intervention strategies. | |
| Miki et al. | Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. | |
| EP1799713B1 (en) | Polypeptide compounds for inhibiting angiogenesis and tumor growth | |
| Gong | Isoforms of receptors of fibroblast growth factors | |
| Matsumoto et al. | The distribution of tenascin-X is distinct and often reciprocal to that of tenascin-C. | |
| EP1549679B1 (en) | Fusion protein comprising angiopoietin receptor-binding and a multimerization domain | |
| RU2250213C2 (ru) | Выделенный белок фактора роста кератиноцита (kgf), рекомбинантная молекула днк, вектор, способ конструирования клетки-хозяина, способ получения белка, фармацевтическая композиция | |
| JP2020505955A5 (https=) | ||
| JP2019501141A5 (https=) | ||
| JP2021527706A5 (https=) | ||
| US20100215655A1 (en) | Angiogenesis-inhibiting chimeric proteins and the use | |
| JP2009518024A5 (https=) | ||
| JP2004524810A5 (https=) | ||
| JP2022548764A5 (https=) | ||
| JP2015530359A5 (https=) | ||
| CN104086654B (zh) | 人源化修饰型抗CD147嵌合抗体HcHAb18及其应用 | |
| RS54215B1 (sr) | Sastavi i postupci za dijagnozu i tretman raka | |
| KR101910779B1 (ko) | Ｆｇｆｒ１ 세포밖 도메인 조합치료 | |
| WO2000037642A9 (en) | Method of enhancing the biological activity of ligands | |
| EP2462952A1 (en) | Cancer gene therapy using nucleic acids encoding US28 |